X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (345) 345
tetrabenazine - therapeutic use (241) 241
male (208) 208
tetrabenazine (202) 202
index medicus (177) 177
female (172) 172
animals (142) 142
pharmacology & pharmacy (124) 124
clinical neurology (119) 119
middle aged (116) 116
adult (97) 97
huntington disease - drug therapy (86) 86
tetrabenazine - analogs & derivatives (86) 86
aged (84) 84
rats (79) 79
tetrabenazine - pharmacology (78) 78
neurosciences (73) 73
chorea (68) 68
tetrabenazine - adverse effects (60) 60
adrenergic uptake inhibitors - therapeutic use (58) 58
dopamine (55) 55
tardive dyskinesia (52) 52
movement disorders - drug therapy (47) 47
double-blind (46) 46
psychiatry (46) 46
antipsychotic agents - adverse effects (43) 43
dopamine - metabolism (42) 42
dose-response relationship, drug (42) 42
huntington's disease (40) 40
tetrabenazine - administration & dosage (40) 40
chorea - drug therapy (39) 39
treatment outcome (38) 38
mice (37) 37
movement disorders (37) 37
anti-dyskinesia agents - therapeutic use (36) 36
antipsychotic agents - therapeutic use (36) 36
dyskinesia, drug-induced - drug therapy (36) 36
child (35) 35
neurology (34) 34
clinical trials as topic (32) 32
hyperkinetic movement-disorders (30) 30
tetrabenazine - metabolism (30) 30
vesicular monoamine transport proteins - antagonists & inhibitors (30) 30
adolescent (29) 29
dystonia (29) 29
movement-disorders (29) 29
rats, sprague-dawley (27) 27
vesicular monoamine transport proteins - metabolism (27) 27
motor activity - drug effects (26) 26
vesicular monoamine transporter (26) 26
deutetrabenazine (25) 25
tardive-dyskinesia (25) 25
parkinsons-disease (24) 24
schizophrenia (24) 24
binding (23) 23
brain (23) 23
neuroleptics (23) 23
tardive dyskinesia - drug therapy (23) 23
therapy (23) 23
time factors (23) 23
valbenazine (23) 23
valine - analogs & derivatives (23) 23
vmat2 (23) 23
adrenergic uptake inhibitors - pharmacology (22) 22
care and treatment (22) 22
huntington disease - physiopathology (22) 22
huntington's chorea (22) 22
levodopa - therapeutic use (22) 22
depression (21) 21
drug therapy (21) 21
drugs (21) 21
huntington disease (21) 21
parkinson's disease (21) 21
tourette syndrome - drug therapy (21) 21
medicine & public health (20) 20
tetrabenazine - pharmacokinetics (20) 20
valine - therapeutic use (20) 20
disease models, animal (19) 19
dyskinesia (19) 19
dystonia - drug therapy (19) 19
parkinson disease - drug therapy (19) 19
reserpine - pharmacology (19) 19
reserpine - therapeutic use (19) 19
severity of illness index (19) 19
tics (19) 19
analysis (18) 18
article (18) 18
botulinum toxin (18) 18
brain - metabolism (18) 18
haloperidol (18) 18
monoamine transporter (18) 18
positron-emission-tomography (18) 18
research article (18) 18
tetrabenazine - chemistry (18) 18
clinical trials (17) 17
haloperidol - therapeutic use (17) 17
hyperkinesis - drug therapy (17) 17
pediatrics (17) 17
transporter (17) 17
antiparkinson agents - therapeutic use (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (479) 479
Spanish (8) 8
French (6) 6
German (6) 6
Danish (3) 3
Italian (3) 3
Japanese (3) 3
Polish (2) 2
Russian (2) 2
Croatian (1) 1
Hungarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Psychiatry and Clinical Neurosciences, ISSN 1323-1316, 06/2015, Volume 69, Issue 6, pp. 321 - 334
Tardive dyskinesia is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking... 
first‐generation agents | schizophrenia | management | second‐generation agents | tardive dyskinesia | second-generation agents | first-generation agents | VITAMIN-E TREATMENT | NEUROTROPHIC FACTOR LEVELS | SCHIZOPHRENIC-PATIENTS | PSYCHIATRY | GINKGO-BILOBA | CHAIN AMINO-ACIDS | NEUROSCIENCES | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | HYPERKINETIC MOVEMENT-DISORDERS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ESSENTIAL FATTY-ACIDS | Stilbenes - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Propranolol - therapeutic use | Leucine - therapeutic use | Dopamine Agents - therapeutic use | Amantadine - therapeutic use | Piracetam - therapeutic use | Pyridoxine - therapeutic use | Clonazepam - therapeutic use | Drugs, Chinese Herbal - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Anticonvulsants - therapeutic use | Nootropic Agents - therapeutic use | Isoleucine - therapeutic use | Vitamins - therapeutic use | Ginkgo biloba | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Movement Disorders - etiology | Piracetam - analogs & derivatives | Melatonin - therapeutic use | Fatty Acids, Omega-3 - therapeutic use | Valine - therapeutic use | Isoxazoles - therapeutic use | Plant Extracts - therapeutic use | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use | Schizophrenia | Movement disorders | Tardive dyskinesia | Medical research
Journal Article
Journal Article
Journal Article